The role of miR-18a in gastric cancer angiogenesis

Hepato-Gastroenterology

Volumn 60, Issue 127, 2013, Pages 1809-1813

  Zheng, Yongbin ^a   Li, Shengbo ^a   Ding, Yu ^a   Wang, Qiushuang ^a   Luo, Haiping ^a   Shi, Qiang ^a   Hao, Zhinan ^a   Xiao, Gaochun ^a   Tong, Shilun ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Gastric cancer; Microrna18a

Indexed keywords

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD31; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOPROTEINS; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893970621     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge13256     Document Type: Article

References (26)

1. Hoff PM, Machado KK: Role of angiogenesis in the pathogenesis of cancer. Cancer Treatment Reviews 2012; 38:825-833.
2. Shojaei F: Anti-angiogenesis therapy in cancer: Current challenges and future perspectives. Cancer Letters 2012; 320:130-137.
3. Leite de Oliveira R, Hamm A, Mazzone M: Growing tumor vessels: More than one way to skin a cat -Implications for angiogenesis targeted cancer therapies. Molecular Aspects of Medicine 2011; 32:71-97.
4. Zhang W, He XJ, Ma YY, et al.: Inducible nitric oxide synthase expression correlates with angiogenesis, lymphangiogenesis, and poor prognosis in gastric cancer patients. Human Pathology 2011; 42:1275-1282.
5. Fuereder T, Jaeger-Lansky A, Hoeflmayer D, et al.: mTOR inhibition by everolimus counteracts VEGF induction by sunirinib and improves anti-tumor activity against gastric cancer in vivo. Cancer Letters 2010; 296:249-256.
6. Kizaka-Kondoh S, Tanaka S, Harada H, et al.: The HIF-1-active microenvironment: An environmental target for cancer therapy. Adv Drug Delivery Rev 2009; 61:623-632.
7. Jansson MD, Lund AH: MicroRNA and cancer. Molecular Oncology 2012; 6:590-610.
8. Catto JWF, Alcaraz A, Bjarteli AS, et al.: MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review. Eur Urology 2011; 59:671-681.
9. Tsangand WP, Kwok TT: The miR-18a microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 2009; 30(6):953-959.
10. Mendell JT: MiRiad roles for the miR-17-92 cluster in development and dieease. Cell 2008; 133(2):217-222.
11. Esquela-Kerscher A, Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-269.
12. Katada T, Ishiguro H, Kuwabara Y, et al.: MicroRNA expression profile in undifferentiated gastric cancer. Int J Oncol 2009; 34:537-542.
13. Liu T, Tang H, Lang Y, et al.: MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 2009; 273:233-242.
14. Xiao B, Guo J, Miao Y, et al.: Detection of miR-106a in gastric carcinoma and its clinical significance. Clin Chim Acta 2009; 400(1-2):97-102.
15. Fasanaro P, D'Alessandra Y, Di Stefano V, et al.: MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine-kinase ligand Ephrin-A3. J Biol Chem 2008; 283(23):15878-15883.
16. Ji R, Cheng Y, Yue J, et al.: MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007; 100(5):1579-1588. (Pubitemid 46897261)
17. Dews M, Homayouni A, Yu D, et al.: Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006; 38(9):1060-1065. (Pubitemid 44325933)
18. Lee DY, Deng Z, Wang CH, et al.: MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA 2007; 104(51):20350-20355.
19. Hua Z, Lv Q, Ye W, et al.: MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE 2006; 1(1):e116.
20. Donnern T, Fenton CG, Lonvik K, et al.: MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS ONE 2012; 7(1):e29671.
21. Maeda K, Chung YS, Ogawa Y, et al.: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77(5):858-863. (Pubitemid 26061277)
22. Inoki K, Corradetti MN, Guan KI: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37:19-24. (Pubitemid 40070934)
23. Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22. (Pubitemid 47001784)
24. Brugarolas JB, Vazquez F, Reddy A, et al.: TSC2 regulates VEGF through mTOR-dependent and-independent pathways. Cancer Cell 2003; 4:147-158. (Pubitemid 37045363)
25. Lang SA, Gaumann A, Koehl GE, et al.: Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Inter J Cancer 2007; 8:1803-1810. (Pubitemid 46399369)
26. Murayama T, Inokuchi M, Takagi Y, et al.: Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer 2009; 100:782-788.